Combined Therapy with Anthracyclines and GnRH Analogues for Breast Cancer: Impact on Ischemic Heart Disease

The combination of classic chemotherapy agents like anthracyclines with novel targeted medications has had a positive impact on women’s survival from breast cancer. GnRH analogues are primarily employed to temporarily suppress ovarian function in premenopausal women with hormone-receptor-positive (H...

Descripción completa

Detalles Bibliográficos
Autores principales: Bergami, Maria, Manfrini, Olivia, Cenko, Edina, Bugiardini, Raffaele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10648997/
https://www.ncbi.nlm.nih.gov/pubmed/37959257
http://dx.doi.org/10.3390/jcm12216791
_version_ 1785135466964582400
author Bergami, Maria
Manfrini, Olivia
Cenko, Edina
Bugiardini, Raffaele
author_facet Bergami, Maria
Manfrini, Olivia
Cenko, Edina
Bugiardini, Raffaele
author_sort Bergami, Maria
collection PubMed
description The combination of classic chemotherapy agents like anthracyclines with novel targeted medications has had a positive impact on women’s survival from breast cancer. GnRH analogues are primarily employed to temporarily suppress ovarian function in premenopausal women with hormone-receptor-positive (HR+) breast cancer. Despite their benefits, the true degree of their collateral effects has been widely understudied, especially when it comes to ischemic heart disease. This review aims at summarizing the current state of the art on this issue, with particular focus on the risk for cardiotoxicity associated with the combined use of GnRH analogues and anthracyclines.
format Online
Article
Text
id pubmed-10648997
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106489972023-10-27 Combined Therapy with Anthracyclines and GnRH Analogues for Breast Cancer: Impact on Ischemic Heart Disease Bergami, Maria Manfrini, Olivia Cenko, Edina Bugiardini, Raffaele J Clin Med Review The combination of classic chemotherapy agents like anthracyclines with novel targeted medications has had a positive impact on women’s survival from breast cancer. GnRH analogues are primarily employed to temporarily suppress ovarian function in premenopausal women with hormone-receptor-positive (HR+) breast cancer. Despite their benefits, the true degree of their collateral effects has been widely understudied, especially when it comes to ischemic heart disease. This review aims at summarizing the current state of the art on this issue, with particular focus on the risk for cardiotoxicity associated with the combined use of GnRH analogues and anthracyclines. MDPI 2023-10-27 /pmc/articles/PMC10648997/ /pubmed/37959257 http://dx.doi.org/10.3390/jcm12216791 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Bergami, Maria
Manfrini, Olivia
Cenko, Edina
Bugiardini, Raffaele
Combined Therapy with Anthracyclines and GnRH Analogues for Breast Cancer: Impact on Ischemic Heart Disease
title Combined Therapy with Anthracyclines and GnRH Analogues for Breast Cancer: Impact on Ischemic Heart Disease
title_full Combined Therapy with Anthracyclines and GnRH Analogues for Breast Cancer: Impact on Ischemic Heart Disease
title_fullStr Combined Therapy with Anthracyclines and GnRH Analogues for Breast Cancer: Impact on Ischemic Heart Disease
title_full_unstemmed Combined Therapy with Anthracyclines and GnRH Analogues for Breast Cancer: Impact on Ischemic Heart Disease
title_short Combined Therapy with Anthracyclines and GnRH Analogues for Breast Cancer: Impact on Ischemic Heart Disease
title_sort combined therapy with anthracyclines and gnrh analogues for breast cancer: impact on ischemic heart disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10648997/
https://www.ncbi.nlm.nih.gov/pubmed/37959257
http://dx.doi.org/10.3390/jcm12216791
work_keys_str_mv AT bergamimaria combinedtherapywithanthracyclinesandgnrhanaloguesforbreastcancerimpactonischemicheartdisease
AT manfriniolivia combinedtherapywithanthracyclinesandgnrhanaloguesforbreastcancerimpactonischemicheartdisease
AT cenkoedina combinedtherapywithanthracyclinesandgnrhanaloguesforbreastcancerimpactonischemicheartdisease
AT bugiardiniraffaele combinedtherapywithanthracyclinesandgnrhanaloguesforbreastcancerimpactonischemicheartdisease

Ejemplares similares